Cancer News and Research

Latest Cancer News and Research

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

FDA continues review of BSD Medical's HDE for the BSD-2000 Hyperthermia System

BSD Medical Corporation (NASDAQ: BSDM) (www.bsdmedical.com) reported today that the U.S. Food and Drug Administration (FDA) continues its review of the Company's Humanitarian Device Exemption (HDE) marketing submission for the Company’s BSD-2000 Hyperthermia System.

19 Sep 2009

Jennerex raises funds through private placement for clinical development programs

Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), a clinical stage biopharmaceutical company developing a proprietary breakthrough product class of targeted oncolytic virus therapeutics, today announced the Second and final closing of a private placement financing with aggregate gross proceeds of US $5,611,475, exceeding the target of US $5 million.

19 Sep 2009

Array Biopharma and Piper Jaffray enter into Equity Distribution Agreement

Array BioPharma Inc. (Nasdaq: ARRY) today announced it had entered into an Equity Distribution Agreement with Piper Jaffray & Co. The Equity Distribution Agreement provides that the Company may offer and sell shares of its common stock, par value $0.001 per share, having an aggregate offering price of up to $25,000,000 from time to time through Piper Jaffray, as sales agent.

19 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Prostate cancer more prevalent in African-American men

A new guide, Straight Talk for African-American Men and their Families, is now available from the Prostate Cancer Foundation (PCF). It was produced in alliance with Charlie Wilson, famed R&B singer and recent prostate cancer survivor.

19 Sep 2009

Bioniche announces fiscal 2009 year-end results

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

19 Sep 2009

Zila completes merger agreement with TOLMAR Holding

Zila, Inc. today announced the completion of the merger with a subsidiary of TOLMAR Holding, Inc. Pursuant to the merger agreement between the companies, at the effective time of the merger all outstanding shares of Zila’s common stock were converted into the right to receive $0.45 per share in cash.

19 Sep 2009

Metabasis Therapeutics receives notice letter from Nasdaq

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced today that on September 15, 2009, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”), notifying the Company that based upon the closing bid price of its common stock for the last 30 consecutive business days, the Company did not maintain a minimum closing bid price of $1.00 per share or more that is required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

18 Sep 2009

EPO and growth factor therapy safe for anemic MDS patients

Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).

18 Sep 2009

Research program to study personalized medicine

A new collaborative research program that will use the power of metabolomic profiling to help advance the concept of personalized medicine was announced September 17, 2009 by the Burnham Institute for Medical Research and the Sarah W. Stedman Nutrition and Metabolism Center at Duke University Medical Center.

18 Sep 2009

Scientific discoveries must be translated into practical applications to improve patients' health

Experts gathered on Capitol Hill today to address the impact of policies related to translational research and U.S. medical innovation. The briefing, titled Translational Research: From Bench to Bedside, was sponsored by the Council for American Medical Innovation as the second in a three-part series, Recovery Through Discovery, which examines medical innovation as a driver of U.S. economic recovery and enhanced global leadership in science.

18 Sep 2009

JPO to grant patent from the Tuschl III patent series

Regulus Therapeutics Inc., Alnylam Pharmaceuticals, Inc., and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the Japan Patent Office (JPO) has notified the Max Planck Society of its intent to grant a patent from the Tuschl III patent series (JP Application Number 2003-532675).

18 Sep 2009

No unsafe levels of air pollutants or metals detected at schools in Beaver and Erie counties: DEP

Air quality sampling by the state Department of Environmental Protection at schools in Beaver and Erie counties has not detected unsafe levels of air pollutants or metals, Environmental Protection Secretary John Hanger said today.

18 Sep 2009

Research to identify breast cancer disparities

In an effort to continue to deliver on its vision of a world without breast cancer, Susan G. Komen for the Cure,((R) )San Diego conducted an in-depth, county-wide research and community needs assessment to identify disparities in breast cancer across populations.

18 Sep 2009

Raindance Technologies and CLC to develop software for resequencing analysis

RainDance Technologies and CLC bio today announced a partnership to develop specialized software for the analysis of targeted resequencing data generated by workflows incorporating RainDance’s Sequence Enrichment Solution and next generation DNA sequencing platforms.

18 Sep 2009

Pharmacyclics announces financial results for fourth quarter and FY 2009

Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.

18 Sep 2009

Researchers study the role of stem cells in development of liver cancer

Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer.

18 Sep 2009

Study reveals microRNAs affect tumor progression

UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.

18 Sep 2009

National Institutes of Health funds for thymus research

The National Institutes of Health have awarded, as part of the American Reinvestment and Recovery Act, a two-year, $2 million grant to a University of Georgia genetics researcher and her colleagues for studies on the thymus, the organ in humans that produces disease-fighting T-cells.

18 Sep 2009